Jeffrey E. Gershenwald, M.D.

Peer-Reviewed Articles

1. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472-492, 2017. e-Pub 2017. PMID: 29028110.
2. Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SK. Assessment of compliance with Texas legislation banning indoor UV tanning by minors. JAMA Dermatol 153(2):228-229, 2017. e-Pub 2016. PMID: 27829081.
3. Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, Gimotty PA, Guinney JH, Halabi S, Lazar AJ, Mahar AL, Patel T, Sargent DJ, Weiser MR, Compton C, members of the AJCC Precision Medicine Core. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin 66(5):370-4, 2016. e-Pub 2016. PMID: 26784705.
4. Mahar AL, Compton C, Halabi S, Hess KR, Gershenwald JE, Scolyer RA, Groome PA. Critical assessment of clinical prognostic tools in melanoma. Ann Surg Oncol 23(9):2753-61, 2016. e-Pub 2016. PMID: 27052645.
5. Tripp MK, Peterson SK, Prokhorov AV, Shete SS, Lee JE, Gershenwald JE, Gritz ER. Correlates of sun protection and sunburn in children of melanoma survivors. Am J Prev Med 51(3):e77-85, 2016. e-Pub 2016. PMID: 27067306.
6. Najita JS, Swetter SM, Geller AC, Gershenwald JE, Zelen M, Lee SJ. Sex differences in age at primary melanoma diagnosis in a population-based analysis (US Surveillance, Epidemiology, and End Results, 2005-2011). J Invest Dermatol 136(9):1894-7, 2016. e-Pub 2016. PMID: 27251792.
7. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-837, 2016. e-Pub 2016. PMID: 27301722.
8. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res 29(4):404-16, 2016. e-Pub 2016. PMID: 27087480.
9. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clin Cancer Res 22(12):3016-24, 2016. e-Pub 2016. PMID: 26783288.
10. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. J Clin Oncol 34(15):1741-7, 2016. e-Pub 2016. PMID: 27001565.
11. McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RC, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Davidson BS, Gershenwald JE, Hagendoorn LJ, Stromberg AJ, Scoggins CR. Final results of the sunbelt melanoma trial: A multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol 34(10):1079-86, 2016. e-Pub 2016. PMID: 26858331.
12. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2015. PMID: 26645196.
13. Watson M, Thomas CC, Massetti GM, McKenna S, Gershenwald JE, Laird S, Iskander J, Lushniak B. CDC Grand Rounds: Prevention and Control of Skin Cancer. Am J Transplant 16(2):717-20, 2016. PMID: 26824446.
14. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
15. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E immunohistochemical expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma. Hum Pathol 46(8):1101-10, 2015. e-Pub 2015. PMID: 26058727.
16. Bulger AL, Mayer JE, Gershenwald JE, Guild SR, Gottlieb MA, Geller AC. Enforcement provisions of indoor tanning bans for minors: An analysis of the first 6 US states. Am J Public Health 105(8):e10-2, 2015. e-Pub 2015. PMID: 26066916.
17. Cancer Genome Atlas Network; Watson IR, Gershenwald JE, Chin L. Genomic classification of cutaneous melanoma. Cell 16(7):1681-96, 2015. PMID: 26091043.
18. Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer 136(8):1874-80, 2015. e-Pub 2014. PMID: 25196740.
19. Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli M. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol 17(3):311-21, 2015. e-Pub 2015. PMID: 25686251.
20. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135(2):508-15, 2015. e-Pub 2014. PMID: 25148578.
21. Christianson DR, Dobroff AS, Proneth B, Zurita AJ, Salameh A, Dondossola E, Makino J, Bologa CG, Smith TL, Yao VJ, Calderone TL, O'Connell DJ, Oprea TI, Kataoka K, Cahill DJ, Gershenwald JE, Sidman RL, Arap W, Pasqualini R. Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proc Natl Acad Sci U S A 112(8):2521-6, 2015. e-Pub 2015. PMID: 25659743.
22. Watson M, Thomas CC, Massetti GM, McKenna S, Gershenwald JE, Laird S, Iskander J, Lushniak B. CDC Grand Rounds: Prevention and control of skin cancer. MMWR Morb Mortal Wkly Rep 64(47):1312-4, 2015. e-Pub 2015. PMID: 26633233.
23. Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, Lazar AJ, Davies MA. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res 20(21):5527-36, 2014. e-Pub 2014. PMID: 25165098.
24. Iyer JG, Storer BE, Paulson KG, Lemos B, Phillips JL, Bichakjian CK, Zeitouni N, Gershenwald JE, Sondak V, Otley CC, Yu SS, Johnson TM, Liegeois NJ, Byrd D, Sober A, Nghiem P. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol 70(4):637-43, 2014. e-Pub 2014. PMID: 24521828.
25. Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the Melanoma Bridge meeting, Napoli, December 5th-8th 2013. J Transl Med 12(1):277, 2014. e-Pub 2014. PMID: 25348889.
26. Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119(21):3821-9, 2013. e-Pub 2013. PMID: 23922205.
27. Cheng CS, Rai K, Garber M, Hollinger A, Robbins D, Anderson S, Macbeth A, Tzou A, Carneiro MO, Raychowdhury R, Russ C, Hacohen N, Gershenwald JE, Lennon N, Nusbaum C, Chin L, Regev A, Amit I. Semiconductor-based DNA sequencing of histone modification states. Nat Commun 4:2672, 2013. PMID: 24157732.
28. Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JN. Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res 23(4):290-7, 2013. e-Pub 2013. PMID: 23752305.
29. Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK, NISC Comparative Sequencing Program, Chen G, Elnitski LL, Davies MA, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels Y. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110(33):13481-6, 2013. e-Pub 2013. PMID: 23901115.
30. Li C, Yin M, Wang LE, Amos CI, Zhu D, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol 133(7):1813-21, 2013. e-Pub 2013. PMID: 23407396.
31. Slingluff CL, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Olson WC, Gaucher A, Chase CM, Grosh WW, Weiss GR, Wagenseller AG, Olszanski AJ, Martin L, Shea SM, Erdag G, Ram P, Gershenwald JE, Weber MJ. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial (CTEP 7190/ Mel47). Clin Cancer Res 19(13):3611-20, 2013. e-Pub 2013. PMID: 23620404.
32. Guan X, Niu J, Liu Z, Wang LE, Amos CI, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Variants in melanocortin 1 receptor gene contribute to risk of melanoma - a direct sequencing analysis in a Texas population. Pigment Cell Melanoma Res 26(3):422-5, 2013. e-Pub 2013. PMID: 23360207.
33. Ross MI, Gershenwald JE. Sentinel lymph node biopsy for melanoma: A critical update for dermatologists after two decades of experience. Clin Dermatol 31(3):298-310, 2013. PMID: 23608449.
34. Chu VH, Tetzlaff MT, Torres-Cabala CA, Prieto VG, Bassett R, Gershenwald JE, McLemore MS, Ivan D, Wang WL, Ross MI, Curry JL. Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the classification of thin cutaneous melanomas. Biomed Res Int 2013:898719, 2013. e-Pub 2013. PMID: 24369020.
35. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 2012. e-Pub 2012. PMID: 23032743.
36. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014-23, 2012. e-Pub 2011. PMID: 22180178.
37. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A landscape of driver mutations in melanoma. Cell 150(2):251-63, 2012. PMID: 22817889.
38. Cromwell KD, Ross MI, Xing Y, Gershenwald JE, Royal RE, Lucci A, Lee JE, Cormier JN. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res 22(5):376-85, 2012. PMID: 22914178.
39. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, Schacherer CW, Gardner JM, Wang Y, Bishop DT, Barrett JH, GenoMEL Investigators, MacGregor S, Hayward NK, Martin NG, Duffy DL, Q-Mega Investigators, Mann GJ, Cust A, Hopper J, AMFS Investigators, Brown KM, Grimm EA, Xu Y, Han Y, Jing K, McHugh C, Laurie CC, Doheny KF, Pugh EW, Seldin MF, Han J, Wei Q. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 20(24):5012-23, 2011. e-Pub 2011. PMID: 21926416.
40. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-42, 2011. e-Pub 2011. PMID: 22049339.
41. Askew RL, Swartz RJ, Xing Y, Cantor SB, Ross MI, Gershenwald JE, Palmer JL, Lee JE, Cormier JN. Mapping FACT-Melanoma Quality-of-Life Scores to EQ-5D Health Utility Weights. Value Health 14(6):900-6, 2011. e-Pub 2011. PMID: 21914512.
42. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 17(14):4882-91, 2011. e-Pub 2011. PMID: 21632855.
43. Moore-Olufemi S, Herzog C, Warneke C, Gershenwald JE, Mansfield P, Ross M, Prieto V, Lally KP, Hayes-Jordan A. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg 253(6):1211-5, 2011. PMID: 21451389.
44. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 29(16):2199-205, 2011. e-Pub 2011. PMID: 21519009.
45. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, NISC Comparative Sequencing Program, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43(5):442-6, 2011. e-Pub 2011. PMID: 21499247.
46. Patnana M, Bronstein Y, Szklaruk J, Bedi DG, Hwu WJ, Gershenwald JE, Prieto VG, Ng CS. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 66(3):224-36, 2011. e-Pub 2011. PMID: 21295201.
47. Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer 47(1):107-15, 2011. e-Pub 2010. PMID: 20655738.
48. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels Y. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43(11):1119-26, 2011. e-Pub 2011. PMID: 21946352.
49. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63(5):751-61, 2010. e-Pub 2010. PMID: 20646783.
50. Wei X, Prickett TD, Viloria CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, NISC Comparative Sequencing Program, Rosenberg SA, Davies MA, Gershenwald JE, López-Otín C, Samuels Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res 8(11):1513-25, 2010. e-Pub 2010. PMID: 21047771.
51. Chang SB, Askew RL, Xing Y, Weaver S, Gershenwald JE, Lee JE, Royal R, Lucci A, Ross MI, Cormier JN. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol 17(10):2764-72, 2010. e-Pub 2010. PMID: 20336388.
52. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P, AJCC Melanoma Task Force. Predicting survival outcome of localized melanoma: An electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 17(8):2006-14, 2010. e-Pub 2010. PMID: 20379784.
53. Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 116(9):2234-41, 2010. PMID: 20187100.
54. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28(14):2452-9, 2010. e-Pub 2010. PMID: 20368546.
55. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17(2):229-35, 2010. e-Pub 2010. PMID: 20975100.
56. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103(2):129-42, 2010. e-Pub 2010. PMID: 21081714.
57. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 15(24):7538-7546. e-Pub 2009. PMID: 19996208.
58. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK. Final Version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-206, 2009. e-Pub 2009. PMID: 19917835.
59. Petersson F, Diwan AH, Ivan D, Gershenwald JE, Johnson MM, Harrell R, Prieto VG. Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol 36(11):1157-63, 2009. e-Pub 2009. PMID: 19222695.
60. Tellez CS, Shen L, Estécio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Res 19(3):146-55, 2009. PMID: 19441164.
61. Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115(11):2505-13, 2009. e-Pub 2009. PMID: 19309746.
62. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw 7(3):308-17, 2009. PMID: 19401063.
63. Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, Ross MI, Sondak VK, Thompson JF. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 60(5):872-5, 2009. PMID: 19389531.
64. Staquicini FI, Tandle A, Libutti SK, Sun J, Zigler M, Bar-Eli M, Aliperti F, Pérez EC, Gershenwald JE, Mariano M, Pasqualini R, Arap W, Lopes JD. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res 68(20):8419-28, 2008. PMID: 18922915.
65. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99(8):1265-8, 2008. e-Pub 2008. PMID: 18813315.
66. Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 112(9):2030-7, 2008. PMID: 18320602.
67. Gershenwald JE, Andtbacka RHI, Prieto VG, Johnson MM, Diwan AH, Lee JE, Mansfield PF, Cormier JN, Schacherer CW, Ross MI. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 26(26):4296-4303, 2008. e-Pub 2008. PMID: 18606982.
68. Rebhun RB, Lazar AJ, Fidler IJ, Gershenwald JE. Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Met 25(3):191-9, 2008.
69. Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, Kim K, Webster K, Cella D, Palmer JL. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer 112(10):2249-57, 2008.
70. Cormier JN, Xing Y, Ding M, Cantor SB, Salter KJ, Lee JE, Mansfield PF, Gershenwald JE, Ross MI. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol 25(17):2442-8, 2007. PMID: 17557957.
71. Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol 127(2):276-80, 2007. PMID: 16990805.
72. Badgwell B, Xing Y, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Pelvic Lymph Node dissection is beneficial in subsets of patients with node-positive melanoma. Surg Oncol 14(10):2867-75, 2007.
73. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, Lazar AJ, Shen SS, Zhang PS, Reed JA, Gershenwald JE, Raz A, Bar-Eli M. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 12(22):6709-15, 2006. PMID: 17121890.
74. Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 166(17):1907-14, 2006. PMID: 17000949.
75. Rebhun RB, Langley RR, Yokoi K, Fan D, Gershenwald JE, Fidler IJ. Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia 8(9):747-57, 2006. PMID: 16984732.
76. Aloia TA, Gershenwald JE, Andtbacka RH, Johnson MM, Schacherer CW, Ng CS, Cormier JN, Lee JE, Ross MI, Mansfield PF. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 24(18):2858-65, 2006. PMID: 16782925.
77. Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Gutman H, Sabel MS, Carlson GW, McMasters KM, Tyler DS, Goydos JS, Eggermont AM, Nieweg OE, Cosimi AB, Riker AI, Coit D. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 13(6):809-16, 2006. PMID: 16604476.
78. Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, Aloia TA, Curley SA, Camacho LH, Capussotti L, Elias D, Vauthey JN. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 13(5):712-20, 2006. PMID: 16538410.
79. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66(6):3188-96, 2006. PMID: 16540670.
80. Pawlik TM, Ross MI, Prieto VG, Ballo MT, Johnson MM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 106(4):900-6, 2006. PMID: 16411225.
81. Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol 23(25):6054-62, 2005. PMID: 16135473.
82. Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 12(8):587-96, 2005. PMID: 16021533.
83. Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma. Curr Probl Surg 42(7):460-534, 2005. PMID: 16099230.
84. Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 23(21):4588-90, 2005. PMID: 16034040.
85. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Hwu P, Ross MI. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 11(12):1079-84, 2004. PMID: 15576833.
86. Daley MD, Norman PH, Leak JA, Nguyen DT, Bui TP, Kowalski AM, Srejic U, Popat K, Arens JF, Gershenwald JE, Hunt KK, Kuerer HM. Adverse events associated with the intraoperative injection of isosulfan blue. J Clin Anesth 16(5):332-41, 2004. PMID: 15374553.
87. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54(3):131-49; quiz 182-4, 2004. PMID: 15195788.
88. Gershenwald JE, Bar-Eli M. Gene expression profiling of human cutaneous melanoma: are we there yet?. Cancer Biol Ther 3(1):121-3, 2004. PMID: 14764994.
89. McCarty MF, Bielenberg DR, Nilsson MB, Gershenwald JE, Barnhill RL, Ahearne P, Bucana CD, Fidler IJ. Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. Melanoma Res 13(4):379-87, 2003. PMID: 12883364.
90. Rousseau DL, Jr, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10(5):569-74, 2003. PMID: 12794025.
91. Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, Spitz MR, Duvic M. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst 95(4):308-15, 2003. PMID: 12591987.
92. Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KB, Papadopoulos NE, Prieto VG, Ross MI. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 20(23):4555-8, 2002. PMID: 12454112.
93. Sumner WE, 3rd, Ross MI, Mansfield PF, Lee JE, Prieto VG, Schacherer CW, Gershenwald JE. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer 95(2):354-60, 2002. PMID: 12124836.
94. Gershenwald JE, Fidler IJ. Cancer. Targeting lymphatic metastasis. Science 296(5574):1811-2, 2002. PMID: 12052939.
95. Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MI. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 52(4):964-72, 2002. PMID: 11958890.
96. Dessureault S, Soong SJ, Ross MI, Thompson JF, Kirkwood JM, Gershenwald JE, Coit DG, McMasters KM, Balch CM, Reintgen D. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 8(10):766-70, 2001. PMID: 11776489.
97. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635-48, 2001. PMID: 11504745.
98. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622-34, 2001. PMID: 11504744.
99. Gershenwald JE, Sumner W, Calderone T, Wang Z, Huang S, Bar-Eli M. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene 20(26):3363-75, 2001. PMID: 11423987.
100. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, Fenske N, Glass F, Balch CM, Coit DG. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 19(11):2851-5, 2001. PMID: 11387357.
101. McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, Noyes RD, Viar V, Cerrito PB, Edwards MJ. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?. Ann Surg Oncol 8(3):192-7, 2001. PMID: 11314933.
102. Porter GA, Ross MI, Berman RS, Sumner WE, 3rd, Lee JE, Mansfield PF, Gershenwald JE. How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?. Surgery 128(2):306-11, 2000. PMID: 10923009.
103. Gershenwald JE, Berman RS, Porter G, Mansfield PF, Lee JE, Ross MI. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol 7(3):226-31, 2000. PMID: 10791854.
104. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 7(2):160-5, 2000. PMID: 10761797.
105. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17(3):976-83, 1999. PMID: 10071292.
106. Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M, Lee JJ, Ross MI. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124(2):203-10, 1998. PMID: 9706139.
107. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch CM, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16(6):2253-60, 1998. PMID: 9626228.
108. Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, Ross MI. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol 5(4):322-8, 1998. PMID: 9641453.
109. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, Bar-Eli M. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 273(26):16501-8, 1998. PMID: 9632718.
110. Gershenwald JE, Fong YM, Fahey TJ, 3rd, Calvano SE, Chizzonite R, Kilian PL, Lowry SF, Moldawer LL. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A 87(13):4966-70, 1990. PMID: 1695006.
111. Gershenwald JE, Bensadoun A, Saluja A. Monoclonal antibodies to avian lipoprotein lipase. Purification of the enzyme by immunoaffinity chromatography. Biochim Biophys Acta 836(3):286-95, 1985. PMID: 4041471.

Invited Articles

1. Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous Melanoma. Lancet 402(6th):485-502, 2023. PMID: 37499671.
2. Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin 66(6):460-80, 2016. e-Pub 2016. PMID: 27232110.
3. Asare EA, Washington MK, Gress DM, Gershenwald JE, Greene FL. Improving the quality of cancer staging. CA Cancer J Clin 65(4):261-3, 2015. e-Pub 2015. PMID: 25952338.
4. Sondak VK, Wong SL, Gershenwald JE, Thompson JF. Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. Am Soc Clin Oncol Educ Book 2013:320-5, 2013. PMID: 23714536.
5. Boland GM, Gershenwald JE. Sentinel lymph node biopsy in melanoma. Cancer J 18(2):185-91, 2012. PMID: 22453020.
6. Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol 104(4):341-53, 2011. PMID: 21858828.
7. Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol 104(4):379-85, 2011. PMID: 21858832.
8. Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, Sleeman JP, Gershenwald JE. Lymphangiogenesis and hemangiogenesis: Potential targets for therapy. J Surg Oncol 103(6):489-500, 2011. PMID: 21480241.
9. Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet M. Cutaneous melanoma: A model to study cancer metastasis. J Surg Oncol 103(6):538-49, 2011. PMID: 21480247.
10. Gershenwald JE, Ross MI. Sentinel lymph node biopsy for cutaneous melanoma. N Engl J Med 364(18):1738-45, 2011. e-Pub 2011. PMID: 21542744.
11. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am 20(1):1-17, 2011. PMID: 21111956.
12. Ross MI, Thompson JF, Gershenwald JE. Sentinel lymph node biopsy for melanoma: Critical assessment at its twentieth anniversary. Surg Oncol Clin N Am 20(1):57-78, 2011. PMID: 21111959.
13. Davies MA, Gershenwald JE. Targeted therapy for melanoma: A primer. Surg Oncol Clin N Am 20(1):165-80, 2011. PMID: 21111965.
14. Berman R, Kurtzman S, Posner M, Gershenwald. Society of Surgical Oncology fellowship training - Where we have been, where we are now, and where we are going. J Surg Oncol 100(3):179-81, 2009. e-Pub 2009. PMID: 19444817.
15. Gershenwald JE, Petrelli N. Fellowship training in surgical oncology - an international affair. Surg Oncol 17(4):277-9, 2008. e-Pub 2008. PMID: 18672361.
16. Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Onc Clin N Am 16(2):430-30, 2007.
17. Gershenwald JE, Ross MI. Practice point: Is sentinel-node biopsy superior to nodal observation in melanoma?. Nat Clin Pract Oncol 4(5):278-9, 2007.
18. Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma. Curr Probl Surg 42(7):455-534, 2005.
19. Pawlik TM, Gershenwald JE. Sentinel lymph node biopsy for melanoma. Contemp Surg 61(4):175-82, 2005.
20. Pawlik TM, Ross MI, Gershenwald JE. Lymphatic mapping in the molecular era. Ann Surg Oncol 11(4):362-74, 2004. PMID: 15070595.
21. Bedrosian I, Gershenwald JE. Surgical clinical trials in melanoma. Surg Clin North Am 83(2):385-403, 2003. PMID: 12744615.

Editorials

1. Gershenwald JE, Halpern AC, Sondak VK. Melanoma prevention-avoiding indoor tanning and minimizing overexposure to the sun. JAMA 316(18):1913-1914, 2016. PMID: 27824997.
2. Gershenwald JE, Guy GP. Stemming the rising incidence of melanoma: Calling prevention to action. J Natl Cancer Inst 108(1):1-3, 2016. PMID: 26563358.
3. Balch CM, Gershenwald JE. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med 370(7):663-4, 2014. PMID: 24521113.
4. Gershenwald JE, Coit DG, Sondak VK, Thompson JF. The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. Ann Surg Oncol 19(11):3301-3, 2012. PMID: 22868918.
5. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM Staging System for Cutaneous Melanoma and Beyond. Ann Surg Oncol 17(6):1475-77, 2010. PMID: 20300965.
6. Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?. Ann Surg Oncol 15(3):670-3, 2008.

Book Chapters

1. Gershenwald JE, Scolyer RA, Hess KR, Thompson JF, Long GV, Ross MI, Lazar AJ, Atkins MB, Balch CM, Barnhill R, Bilimoria KY, Brierley JD, Buzaid AC, Byrd DR, Chapman PB, Cochran AJ, Coit DG, Eggermont AM, Elder DE, Faries MB, Flaherty KT, Garbe C, Gardner JM, Gimotty PA, Halpern AC, Haydu LE, Johnson T, Kirkwood JM, Lee AWM, McArthur GA, Mihm MC, Prieto VG, Sober AJ, Wahl RL, Wong SL, Sondak VK. Melanoma of the Skin. In: AJCC Cancer Staging Manual. 8th. Springer: Switzerland, 563-85, 2017.
2. Gress DM, Edge SB, Greene FL, Washington MK, Asare EA, Brierley JD, Byrd DR, Compton CC, Jessup JM, Winchester DP, Amin MB, Gershenwald JE. Principles of Cancer Staging. In: AJCC Cancer Staging Manual. 8th. Springer: Switzerland, 3-30, 2017.
3. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM and Meyer LR. Organization of the AJCC Cancer Staging Manual. In: AJCC Cancer Staging Manual. 8th. Springer: Switzerland, 31-37, 2017.
4. Compton CC, Hess KR, Halabi S, Balis UGJ, Gershenwald JE, Gimotty PA, Guinney J, Lazar AJ, Lu Y, Mahar AL, Mariotto A, Moons KGM, Patel SG, Sargent DJ, Weiser MR, Kattan MW. Risk models for individualized prognosis in the practice of precision oncology. In: AJCC Cancer Staging Manual. 8th. Springer: Switzerland, 47-54, 2017.
5. Boland GM, Gershenwald JE. Principles of Melanoma Staging. In: Melanoma. Springer: Switzerland, 131-48, 2016.
6. Berman RS, Gershenwald JE. Wide excision of primary cutaneous melanoma. In: Operative Techniques in Surgery. Wolters Kluwer Health: China, 1535-45, 2015.
7. Curry JL, Davies MA, Calderone TL, Nathanson K, Prieto VG, Gershenwald JE. Tissue resources for clinical use and marker studies in melanoma. In: Molecular Diagnostics for Melanoma, Methods and Protocols, 679-95, 2014.
8. Boland GM, Gershenwald JE. Melanoma Survivorship Management. In: Advances in Cancer Survivorship Management. Springer: New York, 219-40, 2014.
9. Andtbacka RI, Gershenwald JE. Lymphatic mapping and sentinel lymph node biopsy. In: Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge: New York, 501-15, 2011.
10. Gershenwald JE, Ballo MT, Myers JN. Regional management of melanoma in the clinically node-negative neck. In: Cutaneous Malignancy of the Head and Neck. Plural Publishing, Inc: San Diego, CA, 343-71, 2011.
11. Gershenwald JE. Prognostic factors and staging in melanoma. In: Cancer of the Skin. 2nd. Elsevier Inc: United Kingdom, 282-94, 2011.
12. Patnana M, Gershenwald JE, Hwu WJ, Ng CS. Diagnostic imaging for the radiologists, medical oncologists and surgical oncologists. In: Oncologic Imaging for the Practicing Radiologist, Medical Oncologist and Surgeon. Bermedica Production, Ltd: Columbia, 1-19, 2011.
13. Gershenwald JE, Hwu Patrick. Melanoma. In: Cancer Medicine. 8th. People's Medical Publishing House - USA: Shelton, 1459-86, 2010.
14. Gershenwald JE, Balch CM, Thompson JF. Intraoperative mapping and sentinel node technology. In: Cutaneous Melanoma. 5th. Quality Medical Publishing: St. Louis, 2009.
15. Gershenwald JE, Balch CM, Soong S, Thompson JF. Prognostic factors and natural history of melanoma. In: Cutaneous Melanoma. 5th. Quality Medical Publishing: St. Louis, 35-64, 2009.
16. Balch CM, Gershenwald JE, Soong S, Sober A, Kirkwood J. Melanoma staging and classification. In: Cutaneous Melanoma. 5th. Quality Medical Publishing: St. Louis, 65-85, 2009.
17. Pytowski B, Gershenwald JE. Therapeutic targeting of the lymphovascular system in cancer: The promise and challenges. In: From Local Invasion to Metastatic Cancer: Involvement of Distant Sites through the Lymphovascular System. Humana Press: New York, 191-200, 2009.
18. Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd D, Buzaid AC, Cochran A, Coit DG, Ding S, Eggermont AMM, Flaherty KT, Gimotty P, Kirkwood J, McMasters K, Mihm M, Morton D, Ross MI, Sober A, Sondak VK. Melanoma of the skin. In: AJCC Cancer Staging Manual. 7th. Springer: New York, 2009.
19. Ross MI, Gershenwald JE. How we do it: The M. D. Anderson Cancer Center approach. In: Sentinel Lymph Node Biopsy. Martin Dunitz Ltd: London, 143-49, 2001.

Books (edited and written)

1. Amin MB, Edge SB, Greene FL, Schilsky R, Gaspar L, Washington MK, Brookland RK, Brierley JD, Balch CM, Compton CC, Hess KR, Gershenwald JE, Jessup JM, Byrd DR, Winchester DP, Madera M, Asare EA, Eds. AJCC Cancer Staging Manual. 8th Edition. Springer: Switzerland, 2017.
2. Gershenwald, JE, Guest Editor. Surgical Oncology Clinics of North America. In: Melanoma. Ed(s) N Petrelli. 1. Elsevier, Health Sciences: Philadelphia, PA, 1-228, 2011.
3. Gershenwald, JE, Guest Editor. Lymphadenectomy for Malignant Disease. Operative Techniques in General Surgery: New York, 2006.

Letters to the Editor

1. Balch CM, Gershenwald JE, Soong SJ. Reply to J.M. Thomas et al. J Clin Oncol 28: e480-81, 2010.
2. Gershenwald JE, Andtbacka RHI, Ross MI. In Reply to: The Rotterdam criteria for sentinel node tumor load: the simplest prognostic factor?, van Akkooi, AC. J Clin Oncol 26: 6012, 2008.
3. Scolyer RA, Murali R, Gershenwald JE, Cochran AJ, Thompson JF. Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Ann Oncol 18: 806-8, 2007.
4. Pawlik TM, Ross MI, Shaw HM, Thompson JF, Gershenwald JE. Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. Eur J Surg Oncol 31: 323-4, 2005.
5. Scolyer RA, Thompson JF, McCarthy SW, Gershenwald JE, Ross MI, Cochran AJ. Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. J Am Coll Surg 201: 821-3; author reply 823-4, 2005.